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Abstract
Hutchinson-Gilford progeria syndrome (HGPS) is a rare premature aging disorder that belongs to
a group of conditions called laminopathies which affect nuclear lamins. Mutations in two genes,
LMNA and ZMPSTE24, have been found in patients with HGPS. The p.G608G LMNA mutation is
the most commonly reported mutation. The aim of this work was to compile a comprehensive
literature review of the clinical features and genetic mutations and mechanisms of this syndrome
as a contribution to health care workers. This review shows the necessity of a more detailed clinical
identification of Hutchinson-Gilford progeria syndrome and the need for more studies on the
pharmacologic and pharmacogenomic approach to this syndrome.
Introduction
Biological ageing considers that some ageing-associated
changes are programmed while others are stochastic and
unpredictable [1,2]. An alternative to the analysis of aging
is the study of human genetic syndromes whose pheno-
types show specific characteristics of human ageing. Pre-
mature ageing syndromes (or progeroid syndromes)
constitute one of these alternatives since they are consid-
ered to be segmental progeroid syndromes [3].
Hutchinson-Gilford progeria syndrome (HGPS)
Hutchinson-Gilford progeria syndrome (HGPS; OMIM
#176670) is a very rare genetic disease, characterized by
precocious ageing in early infancy, with several clinical
characteristics such as growth retardation after birth, fail-
ure to thrive and skin abnormalities (sclerotic skin dim-
pling and mottling), sleeping with eyes open, circumoral
cyanosis, prominent eyes and cutaneous/scalp vascula-
ture, decreased joint range of motion, micrognathia, pre-
mature atherosclerosis, loss of subcutaneous fat, alopecia,
fingertip tufting, distal-joint abnormalities, altered pig-
mentation and generalized anomaly in bone develop-
ment with pathogenic fracture and osteolysis [4-7].
The syndrome name is derived from the Greek word geras,
meaning "prematurely old." It was first described by
Jonathan Hutchinson in 1886, and named by Hastings
Gilford in 1904. Since its first description in 1886, over
150 cases have been reported in the world [5,8]. These
patients have a short life expectancy with death occurring
in adolescence, most times due to cardiovascular diseases
[7].
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There are other forms of progeria that manifest at several
ages and are characterized by signs of ageing, such as the
following syndromes: Wiedemann-Rautenstrauch,
Cockayne, Werner, Emery-Dreifuss, Rothmund-Thom-
son, and Seckel [5].
The incidence of classic progeria has been estimated to be
1 per 4–8 million live births [9]. Prevalence of sex has not
been evidenced so far. The majority of HGPS patients are
Caucasian [4,5,10]. Over 150 cases have been reported in
the literature throughout the world [11]. The average life
expectancy for a patient with HGPS is 13 years, with an
age range of 7 to 27 years old. Caucasians represent 97%
of patients with HGPS, and cardiovascular abnormalities
account for 75% of death in patients with the syndrome
[10].
The objective of this present work was to carry out a liter-
ature review of the molecular traits and clinical features of
Hutchinson-Gilford progeria syndrome (HGPS), in a
search based on mutations in the genes involved with this
genetic disease.
Methodology
The keywords used for this review were progeria, ageing,
LMNA gene and Hutchinson-Gilford. The search was per-
formed using the international bibliographic databases
and was started in the 1990s and updated to 2008.
Molecular mechanism of laminopathies
HGPS belongs to a group of disorders called laminopa-
thies which affect nuclear lamins and include several phe-
notypes (figure 1). Mutations in the gene LMNA  have
been identified in the majority of cases of HGPS. The gene
LMNA encodes nuclear lamin A, with the predominant
somatic cell isoforms lamin A and C arising by alternative
RNA splicing, which underlies and organizes the inner
surface of the nuclear envelope [12-14]. There are at least
11 distinct diseases associated with >300 different muta-
tions in LMNA [15-17]. Mutations in LMNA have been
detected in 88% of patients with HGPS, while the genetic
mechanism of the remaining 12% is still unknown [3].
Lamins are structural components of the nuclear lamina,
a proteinaceous network underlying the inner nuclear
Structure and function of the nuclear lamina Figure 1
Structure and function of the nuclear lamina. The nuclear lamina lies on the inner surface of the inner nuclear mem-
brane (INM), where it serves to maintain nuclear stability, organize chromatin and bind nuclear pore complexes (NPCs) and a 
steadily growing list of nuclear envelope proteins (purple) and transcription factors (pink). Nuclear envelope proteins that are 
bound to the lamina include nesprin, emerin, lamina-associated proteins 1 and 2 (LAP1 and LAP2), the lamin B receptor (LBR) 
and MAN1. Transcription factors that bind to the lamina include the retinoblastoma transcriptional regulator (RB), germ cell-
less (GCL), sterol response element binding protein (SREBP1), FOS and MOK2. Barrier to autointegration factor (BAF) is a 
chromatin-associated protein that also binds to the nuclear lamina and several of the aforementioned nuclear envelope pro-
teins. Heterochromatin protein 1 (HP1) binds both chromatin and the LBR. ONM, outer nuclear membrane [9].Immunity & Ageing 2009, 6:4 http://www.immunityageing.com/content/6/1/4
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membrane which determines the shape, integrity and size
of the nucleus. Furthermore, lamin plays an important
role in the organization of the pore complex, and recruits
other proteins such as emerin for the nuclear envelope
(figure 2). Lamins A and C are important for nuclear sta-
bility, play a role in transcription regulation in response to
a chemical or mechanical stimulus, and are members of
the intermediate-type filament proteins which also form
part of the nuclear matrix scaffold [15,16]. Due the multi-
ple interactions between chromatin and the nuclear
matrix, mutations in lamins A and C are thought to impair
various nuclear functions including chromatin and chro-
mosome stability, telomere integrity, regulation of tran-
scription, DNA replication, cell cycle control and cellular
differentiation, causing a variety of disorders which first
affect striated muscle, adipocytes and peripheral nerves or
Potential mechanisms of disease Figure 2
Potential mechanisms of disease. A range of molecular and cellular mechanisms are likely to contribute to the diverse 
phenotypes that are seen in the laminopathies, and these mechanisms probably vary depending on the specific mutation. Here, 
as an example, we show a range of putative disease-causing mechanisms for the case of HGPS, in which lamin A is permanently 
farnesylated in the form of progerin. We predict that progerin becomes entrapped in the nuclear membrane as a result of per-
manent farnesylation, resulting in a multitude of downstream effects. Disruption of the normal lamina architecture leads to fra-
gility, vulnerability to mechanical stresses and nuclear blebbing. Other consequences include disrupted interactions with other 
nuclear envelope proteins – such as nesprin, emerin and laminaassociated protein 2 (LAP2) – which leads to their mislocaliza-
tion (that is, emerin is relocalized to the cytoplasm in Lmna -/- mice)74 and clustering of nuclear pores. Disorganization and 
loss of peripheral heterochromatin is also seen, with heterochromatin becoming detached from the nuclear envelope, and dis-
rupted interactions with RNA polymerase II, RNA splicing factors and transcription factors such as the retinoblastoma tran-
scriptional regulator (RB) and sterol response element binding protein (SREBP1), which leads to misregulation of gene 
expression. GCL, germ cell-less [9].
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cause the appearance of premature aging diseases called
laminopathies. A single mutation in lamin A is the cause
of HGPS [3,18,19].
Lamin A in mammals is an element of the polypeptide
family of lamins. Its main components are lamins A, B1,
B2 and C, with molecular weight ranging from 60,000 to
78,000. Lamins A and C are formed by the splicing of
lamin A mRNA. Lamins B1 and B2 are coded by separate
genes, while lamins A and C are identical in the first 566
amino acids. Lamin A is normally synthesized as a precur-
sor molecule (prelamin A). Alternative splicing in exon 11
causes an increase in two different mRNAs which code for
prelamin A and lamin C. Prelamin A, with 664 amino
acids, has 98 carboxyl-terminal amino acids, while lamin
C has 6 carboxyl-terminal amino acids. As lamin A con-
tains a carboxyl-terminal CAAX box (C is cysteine, A is an
aliphatic amino acid and X is any amino acid), it is mod-
ified by farnesylation, which does not occur in lamin C.
Following farnesylation, the cleavage of the three last
amino acids, and methylation of the carboxyl-terminal,
an internal proteolytic cleavage takes place removing the
last 15 coding amino acids, in order to generate a mature
lamin A with 646 amino. Progerin, the altered product in
HGPS, is an incompletely processed lamin A/C that
remains farnesylated, leading to apparent loss of mechan-
ical properties of the nuclear envelope and nuclear matrix.
Cells expressing progerin may experience delayed mitotic
progression which would be consistent with the early
onset and global growth deficit of the HGPS phenotype
[20].
The mutation G608G of HGPS and the consequent abnor-
mal splicing produce a prelamin A that still retains the
CAAX box, but is missing a part for endoproteolytic cleav-
age. Immunofluorescence of HGPS fibroblasts with lamin
A antibodies revealed that 40–50% of the cells displayed
a visible abnormality, an abnormal nuclear envelope
morphology. Thus, this mutation in HGPS seems to act as
a dominant-negative mutation that affects nuclear mor-
phology [21].
Affected nuclear mechanisms and secondary alterations in
gene expression may cause damage to the striated muscle
of individuals with certain mutations in lamin A/C. Dif-
ferent mutations in lamins A and C may cause various tis-
sue-specific pathological phenotypes [19]. There are
several reports about the nuclear abnormalities such as
lobulation or "blebbing" of the nuclear envelope,
increased nuclear surface area, thickening of the nuclear
lamina, loss of peripheral heterochromatin and clustering
of nuclear pore complexes [6,22].
HGPS is related to a mutation in the LMNA gene or in
ZMPSTE2 that codes for a metalloproteinase specifically
involved in the post-translational proteolytic processing
of prelamin A to mature lamin A, which is responsible for
scaffolding and organizing the nuclear envelope surface
(figure 3) [12,23-25].
The inheritance pattern in progeria syndrome is auto-
somal dominant (or less frequently recessive when involv-
ing the ZMPSTE24 gene) [22,26]. All subjects with HGPS
have the disease as result of a de novo mutation (the most
common mutation is p.G608G), as their parents are not
affected. This mutation causes aberrant splicing in exon
11 and the deletion of 50 residues close to the C terminus
of lamin A, including the second ZMPSTE24 cleavage site.
This deletion prevents complete processing of prelamin A,
resulting in the accumulation of a farnesylated lamin A,
known as progerin. Five other different de novo dominant
LMNA mutations have been found less frequently:
p.E145K, p.S143F, p.R644C, p. T10I and p.E578V [13].
Despite being very rare, mutations in HGPS are thought to
have a paternal origin [27].
Clinical manifestations
Patients with HGPS are infants who are healthy at birth
and in the course of 1–2 years present signs of progressive
premature ageing. Initially, sclerodermatous plaques
appear on the skin of the hip and in the upper region of
the lower extremities. These areas grow more and put vir-
tually the entire body at risk, except for the genitals and
some regions of the lower limbs. The production of sweat
is simultaneously decreased and alopecia becomes evi-
dent. Some late signs are hyperpigmentation in sun-
exposed areas, as well as dystrophic nails [5]. The clinical
manifestations of classic progeria include abnormalities
in growth, skin and skeletal and cardiovascular systems,
which are always present after the age of 3 years [6].
The ever present clinical features are prominent scalp
veins, alopecia, bird-like facies, prominent eyes, abnor-
mal dentition and delayed tooth eruption, micrognathia,
short clavicles, horseman stance, pyriform thorax, thin
legs with prominent joints, short stature and low weight
for height, incomplete sexual maturation and lack of sub-
cutaneous fat. The clinical manifestations that may be
apparent or not are sclerodermatous skin, generalized alo-
pecia, eyelashes and eyebrow alopecia, protruding ears
with absent lobes, beaked nose, thin lips with centrofacial
cyanosis, protracted anterior fontanel and high-pitched
voice [4,7,10].
Patients who have most of the aforementioned character-
istics are considered to have a classic case of progeria.
However, individuals who have characteristics more or
less intense of the syndrome are considered patients with
atypical progeria [21].Immunity & Ageing 2009, 6:4 http://www.immunityageing.com/content/6/1/4
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Diagnostic methods
The diagnostic methods of HGPS are clinical (serum lipid
levels, hyaluronic acid excretion, blood count), histologi-
cal (biopsies from areas of abdominal skin with abnormal
nuclear morphology), radiological (abnormality found in
the brain, thorax, long bones and phalanges) and by
screening for mutations in the gene LMNA [12-14].
No laboratory offers a specific molecular genetic testing
for prenatal diagnosis of progeria. Nevertheless, prenatal
testing may be offered to families in which the causative
mutation of the disorder has been identified in a family
member [13].
Some clinical tests for confirmatory diagnosis are sequen-
tial analysis of the gene LMNA, which reveals point muta-
tions in approximately 90% of the patients with HGPS,
and the test for uniparental disomy of chromosome 1 and
deletions associated with HGPS. Imaging studies may also
be performed. Radiography detects manifestations that
usually occur in the skull, thorax, long bones, and
phalanges [10].
Under light microscopy, histological tests using skin biop-
sies from HGPS patients exhibit irregular nuclear enve-
lope outlines, indicating the massive and global
alterations of chromatin functions, including alterations
of gene expression [20]. Tests using keratinocytes from
transgenic mice expressing progerin revealed alterations
in nuclear shape such as decreased nuclear circularity,
resulting in greater nuclear surface area and greater mor-
phological diversity, thereby, microscopic analysis of the
nuclear shape could be an interesting diagnostic alterna-
tive to be studied [14].
Treatment
There is no known cure for progeria. Nonetheless, there
are treatments in order to improve the clinical conditions.
Regular diets may be prescribed, as well as routine immu-
nizations, inspection for cardiovascular diseases, treat-
ment with aspirin, surgical procedures, and physical and
psychological therapies. Children with HGPS must have a
regular diet. Common mulltivitamin tablets are appropri-
ately given in normal doses. Supplements with fluoride
are recommended, since there are dental problems. It is
advised to occasionally give small doses of aspirin to chil-
Biogenesis of lamin A in normal cells and the failure to generate mature lamin A in HGPS Figure 3
Biogenesis of lamin A in normal cells and the failure to generate mature lamin A in HGPS. In the setting of 
ZMPSTE24 deficiency, the final step of lamin processing does not occur, resulting in an accumulation of farnesyl-prelamin A. In 
HGPS, a 50-amino acid deletion in prelamin A (amino acids 607–656) removes the site for the second endoproteolytic cleav-
age. Consequently, no mature lamin A is formed, and a farnesylated mutant prelamin A (progerin) accumulates in cells [25].Immunity & Ageing 2009, 6:4 http://www.immunityageing.com/content/6/1/4
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dren with HGPS, aimed at reducing the occurrence of
heart attack and strokes. Atherosclerosis of the coronary
artery may be diagnosed with an echocardiogram (ECG),
and nitroglycerin may be useful should there be develop-
ment of angina. The drug doses must be based on weight
and the anesthetics must be used cautiously. As these chil-
dren are susceptible to fractures, they should be routinely
accompanied. Due to the susceptibility to dislocation of
the hip bone because of coxa valga, conservative care and
surgical procedures are recommended. In relation to delay
or loss of the first dentition, dental extraction may be rec-
ommended. Physical and psychological therapies are rec-
ommended to help maintain the joints with good
movement amplitude, as well as to foster social interac-
tion, respectively [21].
Another therapeutic approach involves the use of farnesyl-
transferase inhibitors which have been shown to reverse
abnormalities in nuclear morphology in cells expressing
progerin [14]. In vitro studies in fibroblasts have shown
the capacity of farnesyltransferase inhibitors (FTI) to
reverse nuclear alterations [28-30].
Using transgenic mice expressing progerin, an ammeliora-
tion and reversion of cardiovascular phenotype, number
reduction of the spontaneious rib fractures and improved
survival and growth was observed, indicating that these
compounds are an interesting pharmacological alterna-
tive for future treatment of HGPS and progeroid syn-
dromes, as well as anti-aging [14,31,32]. The promising
results with FTIs led to an open-label clinical trial of the
FTI use in HGPS (ClinicalTrials.gov number
NCT000425607) [7].
Other possibilities of treatments studied involves the use
of low levels of growth hormone, but hormonal replace-
ment has had unsatisfactory effects in these patients
[10,11]. The use RNAi or antisense strategies might be use-
ful for reduce the progerin production in HGPS patients,
but this strategy have few studies [31,33,34]. The com-
bined use of a statin and a biphosphonate, compounds
that act in the same mevalonate pathway as FTIs, but the
effect of these drugs alone and combined to treat HGPS
remains an open question [32].
Prognostic
The causes of morbidity in HGPS are difficulty in develop-
ment, cerebrovascular events, vertigo, migraine, necrosis
of the head of the femur and luxation of the hip [5].
Despite all medical and technological advances in cardio-
vascular surgeries (catheterization, cardiac pacemaking),
improvement in patients' life expectancy has not been
achieved, due to their tendency to accumulate atheroma-
tous plaques again. The main cause of death (in 75%
cases) is cardiac or cerebrovascular abnormalities which
include myocardial infarction and congestive heart failure
due to premature atherosclerosis [13]. Psychological sup-
port in these patients is important, as well as a good fam-
ily circle, since there is no mental abnormality. However,
they do have deficient body and physiopathologic control
[5].
Final considerations
While there is a move towards precise molecular classifi-
cation of "laminopathies" rather than the broad clinical
categories in use to date, it appears essential that clinical
features be documented in detail. This may help in
answering parents' questions about prognosis. It may also
contribute to a better understanding of the functions of
lamin A, and may in the future help in determining the
efficacy of pharmacogenetic interventions for Hutchin-
son-Gilford syndrome and other progeroid syndromes.
Due the fact of the cencentration of progering is enhanced
in fibroblast of older persons, HGPS and possibly other
laminopathies may serve as a model for the normal ageing
process.
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